Dicloran

Diclofenac Na

Acute & chronic symptomatic treatment of RA, OA & ankylosing spondylitis.

Adult Initially 100-150 mg daily in 2-3 divided doses. Milder cases & long-term therapy 100 mg daily. Primary dysmenorrhoea 50-150 mg daily, may be increased up to max: 200 mg daily. Childn ≥1 yr & adolescent 0.5-2 mg/kg daily in 2-3 divided doses. Juvenile RA May be increased up to max: 3 mg/kg daily in divided doses. Max: Not to exceed 150 mg daily.

Should be taken on an empty stomach: Swallow whole, do not divide/chew.

Hypersensitivity to diclofenac, aspirin or other NSAIDs-induced asthma, urticaria or other allergic-type reaction. Rhinitis. Severe cardiac failure.

Hypersensitivity. Discontinue use if rash, GI bleeding or ulceration occur. GI disorders, history of gastric or intestinaI ulceration, ulcerative colitis or Crohn's disease; history of serious GI events & other risk factors associated w/ PUD eg, smoking, alcoholism. Not recommended in patients w/ established CV disease (eg, CHF, established ischemic heart disease, peripheral arterial disease) or uncontrolled HTN, or significant risk factors eg, hyperlipidaemia, DM, smoking. Patients w/ CV disease or risk of CV event; serious arteriothrombotic events eg, chest pain, shortness of breath, weakness, slurring of speech; HTN; fluid retention or heart failure. SJS & TEN. May mask signs & symptoms of infections. High-dose & long-term use. Patients on antihypertensive & corticosteroid therapy. Severe hepatic impairment. Avoid use during late pregnancy. Not recommended during lactation. Not recommended in childn & adolescents <14 yr. Elderly.

Peptic ulcers, perforation & GI bleeding; nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis & Crohn's disease.

Increased plasma conc & decreased elimination of lithium. Exacerbated cardiac failure, reduced GFR & increased plasma glycoside levels w/ cardiac glycosides. Enhanced effects of anticoagulant eg, warfarin. Hyperglycaemic & hypoglycaemic effects w/ oral antidiabetic agents. Increased nephrotoxicity w/ ciclosporin & tacrolimus. Reduced mifepristone effect. Increased toxicity of MTX. Increased risk of convulsions associated w/ quinolone antibiotics. Increased frequency of side effects w/ other systemic NSAIDs eg, aspirin. Increased risk of GI bleeding w/ corticosteroids. Increased risk of nephrotoxicity by diuretics. Reduced effect of antihypertensives.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AB05 - diclofenac ; Belongs to the class of acetic acid derivatives and related substances of non-steroidal antiinflammatory and antirheumatic products.

C